Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jean Knapps

Colon & Rectal Surgery Houston, TX Medical Doctor

NPI 1851559728 CMS profile 1398757

1125 Cypress Station Dr Ste G-3, Houston, TX 77090

Open in the dashboard

General payments

$6,545

32 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jean Knapps of Houston, TX is reported in the CMS Open Payments database as having received $6,545 across 32 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Colon & Rectal Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $277 3
2024 General $63 2
2023 General $39 2
2022 General $3,953 13
2021 General $49 2
2020 General $167 1
2019 General $1,997 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jean Knapps
  • Colon & Rectal Surgery median
  • Middle half of Colon & Rectal Surgery
  • National median

In program year 2025, general payments to Jean Knapps were reported at $277. Among 1,481 Colon & Rectal Surgery profiles paid that year, the median was $317 and the middle half received between $109 and $1,248.

Show as a table
Year Jean Knapps Colon & Rectal Surgery median Middle half National median
2019 $1,997 $443 $125–$2,179 $163
2020 $167 $167 $53–$931 $114
2021 $49 $207 $72–$1,272 $132
2022 $3,953 $341 $111–$1,587 $149
2023 $39 $322 $115–$1,420 $160
2024 $63 $328 $112–$1,354 $164
2025 $277 $317 $109–$1,248 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $4,112 14 payments
  2. TELA Bio, Inc. $2,132 10 payments
  3. Tempus AI, Inc $123 1 payment
  4. ERBE USA Inc $36 1 payment
  5. Ethicon US, LLC $34 1 payment
  6. Boston Scientific Corporation $32 1 payment
  7. IBSA Pharma Inc. $20 1 payment
  8. Merck Sharp & Dohme Corporation $20 1 payment
  9. Davol Inc. $19 1 payment
  10. Baxter Healthcare $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,651 7 payments
  2. Food and Beverage $2,185 23 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $695 1 payment
  4. Gift $14 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $4,112 14 payments
  2. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $1,938 8 payments
  3. OviTex $167 1 payment
  4. XT CDX $123 1 payment
  5. Vio3 APC3 $36 1 payment
  6. Enseal X1 $34 1 payment
  7. EXALT $32 1 payment
  8. OviTex 2S $28 1 payment
  9. Tirosint $20 1 payment
  10. Licart $20 1 payment
  11. Other $77 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

308

Median for Colorectal Surgery (Proctology): 106

Drug cost

$8,360

Median for Colorectal Surgery (Proctology): $1,614

Branded share of claims

65.9%

Median for Colorectal Surgery (Proctology): 35.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 108 $6,833
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 95 $963
Pantoprazole Sodium Generic 28 $200
Metronidazole Generic 33 $173
Neomycin Sulfate Generic 33 $163
Omeprazole Generic 11 $28

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,507 Part D prescribers listed as Colorectal Surgery (Proctology); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$89,154

Medicare's payments for the services billed

Medicare patients

243

Average age 74

Services billed

593

137 women, 106 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 43%
Cancer 37%
Chronic kidney disease 36%
Diabetes 33%
Atrial fibrillation 31%
Heart failure 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

32 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Colon & Rectal Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record